Biocon has divested 5.4 per cent stake in its research arm -- Syngene International -- for a little over Rs 1,220 crore through an open market transaction. According to bulk deal data available with the BSE, the company has sold a total of 21,789,164 shares, at an average price of Rs 560.04 apiece, in Syngene International.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.